Lifecycle model-based evaluation of infant 4CMenB vaccination in the UK

J. P. Sevilla (), Daniel Tortorice, David Kantor, John Regan, Kinga H. Meszaros, Ekkehard C. Beck, Najida Begum and David E. Bloom
Additional contact information
J. P. Sevilla: Data for Decisions (DfD) LLC
John Regan: Data for Decisions (DfD) LLC
Kinga H. Meszaros: GSK, Value Evidence
Ekkehard C. Beck: GSK, Value Evidence
Najida Begum: Freelance C/O GSK
David E. Bloom: Data for Decisions (DfD) LLC

The European Journal of Health Economics, 2024, vol. 25, issue 7, No 4, 1133-1146

Abstract: Abstract Objectives Invasive meningococcal disease, an uncommon but severe disease, imposes catastrophic health and economic burdens. Cost–utility analysis (CUA) assumes separability in lifetime health and economic variables and cannot capture the full value of preventing such burdens. We overcome these limitations with a retrospective societal perspective cost–benefit analysis (CBA) of meningococcal serogroup B vaccination (4CMenB) of one infant cohort in the United Kingdom using a health-augmented lifecycle model (HALM) incorporating health’s interactions with consumption, earnings, non-market time and financial risk. Methods We used a static Markov model of vaccination’s health impact and an HALM to estimate the private willingness to pay (PWTP) for the intrinsic and instrumental value of health under perfect capital markets, financial risk protection in the absence of insurance against permanent disability, parental spillovers, and acute phase disability. We estimated social WTP (SWTP) incorporating social severity preferences. We estimated rates of return that inform health payer reimbursement decisions, finance ministry budgeting decisions, and legislature taxation decisions. An expert Advisory Board investigated the validity of applying the HALM to infant 4CMenB. Results The PWTP for a 2 + 1 vaccination schedule is £395, comprising £166 of disability insurance value, £79 of positive parental spillover value, £28 in the value of averting acute phase disability, and £122 in residual intrinsic and instrumental value of health. SWTP is £969. Conclusions HALM-based CBA provides an empirically richer, more utility–theoretically grounded approach to vaccine evaluation than CUA, demonstrating good value for money for legislatures (based on private values) and for all decision-makers (based on social values).

Keywords: Lifecycle model; Health augmented; Cost–benefit analysis; 4CMenB (search for similar items in EconPapers)
JEL-codes: H43 H51 I1 (search for similar items in EconPapers)
Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-023-01654-y Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:25:y:2024:i:7:d:10.1007_s10198-023-01654-y

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-023-01654-y

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().